Last reviewed · How we verify
Sandostatin LAR
Sandostatin LAR is a Somatostatin analog Small molecule drug developed by Pfizer. It is currently FDA-approved for Acromegaly, Carcinoid syndrome, Variceal bleeding in portal hypertension. Also known as: Octreotide acetate, octreotide acetate.
Sandostatin LAR is a long-acting somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.
Sandostatin LAR is a long-acting somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones. Used for Acromegaly, Carcinoid syndrome, Variceal bleeding in portal hypertension.
At a glance
| Generic name | Sandostatin LAR |
|---|---|
| Also known as | Octreotide acetate, octreotide acetate |
| Sponsor | Pfizer |
| Drug class | Somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Oncology |
| Phase | FDA-approved |
Mechanism of action
Sandostatin LAR (octreotide pamoate) is a sustained-release formulation of octreotide, a synthetic analog of somatostatin. It binds to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells, suppressing the secretion of growth hormone, insulin-like growth factor-1 (IGF-1), and other hormones. The long-acting depot formulation provides therapeutic levels for approximately 4 weeks per intramuscular injection.
Approved indications
- Acromegaly
- Carcinoid syndrome
- Variceal bleeding in portal hypertension
- Neuroendocrine tumors
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Headache
- Injection site pain
- Cholelithiasis
- Hyperglycemia
Key clinical trials
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (PHASE3)
- Hoffa's Fat Pad Impingement (HFPI) (PHASE4)
- Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET (PHASE3)
- Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (PHASE1)
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (PHASE3)
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (PHASE1)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (PHASE3)
- 177Lu-DOTATATE for Recurrent Meningioma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sandostatin LAR CI brief — competitive landscape report
- Sandostatin LAR updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Sandostatin LAR
What is Sandostatin LAR?
How does Sandostatin LAR work?
What is Sandostatin LAR used for?
Who makes Sandostatin LAR?
Is Sandostatin LAR also known as anything else?
What drug class is Sandostatin LAR in?
What development phase is Sandostatin LAR in?
What are the side effects of Sandostatin LAR?
What does Sandostatin LAR target?
Related
- Drug class: All Somatostatin analog drugs
- Target: All drugs targeting Somatostatin receptors (SSTR2, SSTR5)
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Endocrinology / Oncology
- Indication: Drugs for Acromegaly
- Indication: Drugs for Carcinoid syndrome
- Indication: Drugs for Variceal bleeding in portal hypertension
- Also known as: Octreotide acetate, octreotide acetate